1. Dietary fructose can specifically increase hepatic de novo lipogenesis (DNL), promote dyslipidemia, decreases insulin sensitivity, and increase visceral adiposity in overweight/obese adults.
2. Fructose may be detrimental in terms of body weight and adiposity and the metabolic indexes associated with the insulin resistance syndrome.
3. Dietary fructose can reduce circulating insulin and leptin, attenuate postprandial suppression of ghrelin, and increase triglycerides in women.
4. Fructose is transported into neocortical cells, including nerve terminals, and that it is metabolized and thereby detoxified primarily through hexokinase activity.
1. Streptozotocin, which produces diabetes mellitus in experimental animals, has been reported to reduce the level of NAD in pancreatic isletsand to inhibit islet synthesis of proinsulin.
2. Streptozotocin can induce pancreatic insulitis, which is a new model of diabetes mellitus.